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Common sequence variation in the VEGFC gene is associated with diabetic retinopathy and diabetic 1 
macular edema in Caucasian patients. 2 
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Abstract 48 
 49 
Objective: To investigate associations between single nucleotide polymorphisms (SNPs) in the VEGFC 50 
gene and the development of diabetic retinopathy (DR) in Caucasian patients with either type 1 (T1DM) or 51 
type 2 (T2DM) diabetes mellitus. 52 
Design: Cross-sectional, case control study. 53 
Participants: Caucasian patients with T1DM or T2DM (n=2899) were recruited from ophthalmology and 54 
endocrine clinics in Australia and the United Kingdom. T2DM patients were required to have DM for at least 55 
5 years, and be on oral hypoglycemic treatment or insulin.  56 
Methods: Participants were categorized according to their worst ever DR grading, as having ‘No DR’ (no 57 
history of non-proliferative DR (NPDR), proliferative DR (PDR) or diabetic macular edema (DME)), or 58 
‘Any DR’ (further sub-classified as NPDR or PDR, without or with DME). Clinical characteristics, glycemic 59 
control (HbA1c), and presence of diabetic complications were determined at recruitment. Genotyping was 60 
performed for 13 VEGFC tag SNPs.  61 
Main Outcome Measures: Odds ratios (OR) were determined for associations with DR of VEGFC tag 62 
SNPs, individually and within haplotypes. Logistic regression was used to adjust for clinical covariates 63 
including DM type, age, sex, DM duration, hypertension, nephropathy, HbA1c
 
and smoking. 64 
Results: Participants with DM but ‘No DR’ (n=980) were compared with 1919 participants with DM and 65 
‘Any DR’. Three VEGFC SNPs were associated with DR following logistic regression: rs17697419 66 
(p=0.001; OR, 0.67; CI, 0.52-0.85), rs17697515 (p=0.001; OR, 0.62; CI, 0.47-0.81) and rs2333526 67 
(p=0.005; OR, 0.69; CI, 0.54-0.90). rs17697515 was also specifically associated with DME in those with 68 
T2DM (p=0.004; OR, 0.53; CI, 0.35-0.82). Haplotype analysis revealed two significantly associated 69 
haplotypes, both protective against DR development.  70 
Conclusions: This study is the first to evaluate sequence variation within the VEGFC gene in diabetes 71 
patients with and without DR. Significant associations were found between VEGFC tag SNPs (individually, 72 
and within haplotypes), and the presence of any DR or DME in Caucasian participants with T1DM and 73 
T2DM. 74 
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Diabetic retinopathy (DR) is a frequent microvascular complication of diabetes mellitus (DM) affecting 98 
approximately 30% of Australians 
1
, and 40% of Americans with DM 
2
. Visual loss occurs when DR 99 
progresses from the early non-proliferative stage to proliferative DR (PDR) or when diabetic macular edema 100 
(DME) develops. PDR is the result of hypoxia induced retinal neovascularization, while DME results from 101 
the increased permeability of dysfunctional capillaries 
3
. Progression from the early stages of DR to 102 
advanced, sight-threatening disease (PDR and DME) is influenced by a number of known risk factors, 103 
especially DM duration and glycemic control 
4,5
. In addition, there is substantial evidence that sight 104 
threatening DR (STDR) has a strong heritable component 
6,7
.  105 
 106 
The effect of genetic variation on specific DR phenotypes in different ethnic populations has been the focus 107 
of recent research 
8-10
. The vascular endothelial growth factor (VEGF) family consists of VEGF-A, -B, -C 108 
and -D and placenta growth factor (PGF), all of which are able to bind to different combinations of the three 109 
tyrosine kinase VEGF receptors (VEGFR-1, -2 and -3) 
11
. VEGF-A, a ligand for VEGFR-2, is the best 110 
studied of these growth factors in relation to DR, and like other factors in the VEGF protein family, is up-111 
regulated in response to the hypoxic conditions of the diabetic retina. In non-proliferative stages of DR local 112 
VEGF-A production increases in areas of capillary non-perfusion, ultimately causing leakage of these retinal 113 
capillaries 
12
. In later stages, VEGF-A is known to promote proliferation of endothelial cells and has been 114 
implicated in the pathological growth of new vessels 
13
. SNPs at the VEGF-A locus have been associated 115 
with the development of DR 
7
, and the therapeutic use of anti-VEGF-A antibodies has been shown to 116 
favorably influence the course of DR 
14
. However, inhibition of VEGF-A does not appear to completely 117 
prevent the angiogenic process 
15
. Investigation of additional factors and their genetic regulation is important 118 
to provide further insights into pathogenesis and opportunities to improve therapy. 119 
VEGF-C functions in lymphangiogenesis through its activation of VEGFR-3, but it also binds VEGFR-2 120 
through which it contributes to the angiogenic process 
11
. VEGF-C expression is markedly increased in 121 
retinal vessels of patients with DM, particularly in those with PDR 
16
, making it an attractive DR 122 
susceptibility gene candidate. To date there has been no investigation of genetic variation in the VEGFC 123 
gene in relation to DM microvascular complications. This study aimed to determine whether tag single 124 
nucleotide polymorphisms (SNPs) in the VEGFC gene are associated with DR in a large, well characterized, 125 
Caucasian cohort of T1DM and T2DM participants.  126 
 127 
 128 
Methods 129 
 130 
The following hospitals in Australia and the United Kingdom were involved as recruitment centers for this 131 
study: Flinders Medical Centre, The Repatriation General Hospital, The Royal Adelaide Hospital, The 132 
Queen Elizabeth Hospital, The Royal Melbourne Hospital, Royal Victorian Eye and Ear Hospital, St 133 
Vincent’s Hospital, Sydney Eye Hospital, and Canberra Hospital in Australia; and The National Institute for 134 
Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL 135 
Institute of Ophthalmology, London, United Kingdom. The study was approved by Human Research Ethics 136 
Committees (HREC) in Australia (Southern Adelaide Clinical HREC; Royal Adelaide Hospital HREC; The 137 
Queen Elizabeth Hospital HREC; Royal Melbourne Hospital HREC; Royal Victorian Eye and Ear Hospital 138 
HREC; St Vincent’s Hospital HREC; South Eastern Sydney Illawarra HREC), and The NHS Health 139 
Research Authority in London. Written informed consent was obtained from each participant. The project 140 
conformed to the tenets of the Declaration of Helsinki. 141 
Individuals with diabetes attending ophthalmology and endocrine clinics at the above named hospitals, and 142 
who met the following inclusion criteria were eligible for participation in this study: (1) T1DM patients at 143 
least 18 years of age, and (2) T2DM patients 18 years of age and older, on medical treatment for DM (either 144 
oral hypoglycemic agents and/or insulin therapy) for a duration of at least 5 years. In brief, the recruitment 145 
process included a questionnaire (including social, demographic and medical history), clinical ophthalmic 146 
examination including DR grading (using the modified Early Treatment Diabetic Retinopathy Study criteria 147 
grading system 
17
), and venous blood collection. A detailed description of recruitment protocols and clinical 148 
characteristics of the first 1669 diabetic participants has been reported previously 
18
. A further 1230 diabetic 149 
participants have since been recruited, including 639 cases with sight-threatening DR (STDR). These 150 
additional cases were recruited via the Registry of Advanced Diabetic Retinopathy (RADAR: 151 
projectradar.com.au), a DNA repository of diabetic patients who have required ophthalmic intervention (in 152 
the form of laser, intravitreal injections or surgery) for DR management. 153 
Participants were categorized according to their worst ever DR grading. ‘Any DR’ was defined as the 154 
presence of at least mild non-proliferative DR (NPDR), PDR or DME in at least 1 eye. STDR described 155 
those with either severe NPDR, PDR, or DME, in at least one eye. Controls were defined as those whose 156 
retinopathy grading has never been worse than minimal NPDR, with no history of DME in either eye. A 157 
subset of the controls with no history of DR or DME were labeled ‘No DR’. Recent biochemistry results 158 
(serum lipids, serum creatinine and urinary albumin) were obtained from patient records. Glycemic control 159 
was determined via the mean of three HbA1c values, either from the year of recruitment, or from the year of 160 
development of STDR for those patients reaching this DR grading. Individuals were classified as having 161 
hypertension if they were on pharmacologic treatment for hypertension, or if they had a systolic or diastolic 162 
blood pressure reading greater than or equal to 140 mmHg or 90 mm Hg, respectively. Hypercholesterolemia 163 
was defined as total cholesterol greater than or equal to 5.5 mM, or current use of lipid-lowering medication. 164 
Nephropathy was defined as the presence of microalbuminuria (30–300 mg/d) or macroalbuminuria (>300 165 
mg/d). DNA was extracted from whole blood using QIAamp Blood DNA Maxi Kits (Qiagen).  166 
Caucasian (CEU) samples genotyped as part of the International HapMap Project 
19
 were used as the basis 167 
for linkage disequilibrium patterns. Tag SNPs across the VEGFC gene, including the promoter region were 168 
selected using the tagger program in Haploview 4.2 
20
. SNPs with minor allele frequency (MAF) greater than 169 
5% in HapMap were considered. 13 tag SNPs (rs17697305, rs2046462, rs17697419, rs7664413, rs6828869, 170 
rs17697515, rs1485766, rs11947611, rs9654285, rs3775195, rs3775194, rs1564922, rs2333526) capturing 171 
104 alleles reaching an r
2
 threshold of 0.8 (mean r
2
 = 0.973) were genotyped in all individuals using iPLEX 172 
Gold chemistry on an autoflex Mass Spectrometer (Sequenom, San Diego, CA). One SNP, rs1564922, did 173 
not type successfully and was excluded from all subsequent analyses. All 12 successfully typed SNPs were 174 
in Hardy-Weinberg equilibrium.  175 
 176 
Baseline demographics between those with and without DR were characterized using basic descriptive 177 
statistics, and compared using a Mann-Whitney U test (for continuous variables) or χ2 test (for dichotomous 178 
variables) using Statistical Package for Social Sciences (SPSS) version 20.0 (IBM SPSS Statistics for 179 
Windows Version 20.0; IBM Corp., Armonk, NY, USA). Testing for association of each SNP with “any DR” 180 
versus “no DR” was undertaken with the χ2 test for univariate analysis and binary logistic regression for 181 
multivariate analysis in PLINK (version 1.06). Multivariate analysis allowed for adjustment of the following 182 
covariates: DM type, age, sex, duration of DM, HbA1c, hypertension, nephropathy and smoking. Association 183 
analyses were also conducted for PDR and DME groups versus controls. Multiple testing of individual SNPs 184 
was adjusted for using Nyholt’s SNP spectral decomposition (SNP SpD) method 21, modified by Li and Ji 22 185 
which estimated nine independent tests. P-value less than 0.006 was required for significance. Haplotype 186 
associations were undertaken in PLINK and adjusted by Bonferroni test for the number of haplotypes in the 187 
block. 188 
 189 
Results 190 
 191 
Caucasian patients with T1DM or T2DM (n=2899) were successfully genotyped at 12 tag SNPs. 980 192 
participants had ‘No DR’ (205 T1DM and 775 T2DM). Of the 1919 participants with ‘Any DR’, 1123 had 193 
NPDR (206 T1DM and 917 T2DM), 734 had PDR (252 T1DM and 482 T2DM) and 909 had DME (140 194 
T1DM and 769 T2DM). Four hundred and ninety-nine of those with DME also had co-existing PDR or 195 
severe NPDR. Baseline characteristics of participants with ‘Any DR’ and those with ‘No DR’ are presented 196 
in Table 1. Amongst T1DM participants, those with DR were older, had longer duration of DM, and had 197 
significantly greater risk factors (including HbA1c, BMI, cholesterol, blood pressure and smoking history) 198 
than those without DR. They were also more likely to have other diabetic microvascular complications 199 
including diabetic nephropathy. In the T2DM group, those with DR were more likely to be male, and of 200 
younger age than those without DR. Longer duration of diabetes and worse glycemic control (as measured 201 
by HbA1c) was seen in the DR group. There was a significantly higher rate of nephropathy in those with DR. 202 
Those with DR were more likely to have a current or previous smoking history, and more likely to have 203 
uncontrolled or treated hyperlipidemia, but there was no difference between groups with respect to other 204 
cardiovascular risk factors, including BMI and hypertension. 205 
 206 
Association of VEGFC SNPs with ‘Any DR’: 207 
Genotype frequencies in patients with and without DR are shown in Table 2 for both T1DM and T2DM 208 
participants. ‘Any DR’ was nominally associated with 5 VEGFC SNPs when populations with T1DM or 209 
T2DM were combined. Three of these (rs17697419, rs17697515 and rs2333526) survived multiple testing 210 
correction for 9 independent tests (p<0.006, Table 3). These top three SNPs also showed significant 211 
associations with ‘Any DR’ following adjustment for clinical covariates (DM type, age, sex, duration of DM, 212 
HbA1c, hypertension, nephropathy and smoking): rs17697419: p=0.001; OR, 0.67; CI, 0.52-0.85; 213 
rs17697515: p=0.001; OR, 0.62; CI, 0.47-0.81; and rs2333526: p=0.005; OR, 0.69; CI, 0.54-0.09.  214 
Analyses stratified by DM type showed similar trends (Table 2). After adjustment for clinical covariates, the 215 
top three SNPs identified from the combined analysis (rs17697419, rs17697515 and rs2333526) reached 216 
significance in the T2DM cohort, which included 852 participants with ‘Any DR’ (rs17697419: p=0.003; OR, 217 
0.65; CI, 0.49-0.86; rs17697515: p=0.003; OR, 0.62; CI, 0.45-0.85; and rs2333526: p=0.003; OR, 0.65; CI, 218 
0.49-0.86). Rs17697419 and rs17697515 showed similar odds ratios in the T1DM cohort after adjustment for 219 
covariates (‘Any DR’ n=345), however statistical significance was not reached. Rs6828869 was found to be 220 
nominally associated with ‘Any DR’ in the TIDM group following multivariate analysis (p=0.035; OR, 0.69; 221 
CI, 0.49-0.97), but did not survive SNP SpD correction for multiple SNP testing.  222 
The linkage disequilibrium pattern between SNPs is presented in Figure 1. Two main blocks of linkage 223 
disequilibrium were observed; block 1 comprising the first six SNPs, and block 2 comprising the remaining 224 
six SNPs. Haplotypes from each block were analysed for association with ‘Any DR’, with T1DM and T2DM 225 
participants combined (Table 4). After adjustment for clinical covariates, there were two haplotypes found to 226 
be associated with DR; haplotype 1 of block 1 (CTACCT) (p=3x10
-4
; OR, 0.59; CI, 0.44-0.79), and 227 
haplotype 1 of block 2 (CATCGT) (p=0.002; OR, 0.65; CI, 0.49-0.86). These two associated haplotypes 228 
survived Bonferroni correction for the haplotypes in each block. A third haplotype, haplotype 8 of block 2, 229 
was also associated with ‘Any DR’, but did not survive Bonferroni correction. 230 
Association of VEGFC SNPs with PDR and DME: 231 
The top three SNPs associated with ‘Any DR’ were investigated for association with PDR and DME 232 
subtypes (Table 5). Rs17697515 was nominally associated with PDR (n=433) and DME (n=425) in the ‘all 233 
DM’ analysis following adjustment for covariates and correction for multiple SNP testing (p=0.007 and 234 
0.009 respectively). In the T2DM cohort alone, which included 361 participants with DME, this SNP was 235 
found to be significantly associated with DME following adjustment and correction (p=0.004; OR, 0.53; CI, 236 
0.35-0.82). There was no association found for rs1769515 with PDR or DME in the TIDM group. 237 
Rs17697419 and rs2333526 were not found to be associated with PDR or DME in the multivariate analysis 238 
in any group.  239 
 240 
Discussion 241 
 242 
Despite extensive research demonstrating a role of the VEGFA gene in neovascularisation pathogenesis, and 243 
more specifically diabetic retinopathy, there is a paucity of data on the potential influence of other VEGF 244 
family genes including VEGFC. To our knowledge, this is the first study to specifically investigate genetic 245 
variation in the VEGFC gene in patients with diabetic retinopathy. 246 
After adjustment for DM type, age, sex, DM duration, HbA1c, hypertension, nephropathy and smoking history, 247 
the A allele of rs17697419, T allele of rs17697515, and T allele of rs2333526 were shown in the current 248 
study to be protective against development of DR. The association was strongest when both T1DM and 249 
T2DM participants were combined in the same analysis. Analysis by DM type showed similar trends, with 250 
all three SNPs again reaching significance in the T2DM cohort after correction for multiple SNP testing. The 251 
lack of association of rs17697419 and 17697515 seen in the T1DM cohort is likely secondary to reduced 252 
power due to the smaller size of the T1DM sample, as suggested by the similar odds ratios at these SNPs 253 
observed in both T1DM and T2DM subsets. Haplotype analysis confirmed a protective role of these top 254 
three ranked SNPs. The minor alleles of rs17697419 and rs17697515 were present in haplotype 1 of block 1, 255 
and together conferred significant protection against DR. The minor allele of rs2333526, was represented in 256 
a second protective haplotype in block 2.  257 
These results are further supported by the strong association of rs17697515 with DME in the T2DM cohort, 258 
which also suggests an important protective role for the T allele of this VEGFC SNP in the subset of patients 259 
with DME. To our knowledge, there have been only two previous studies to report a positive SNP 260 
association for DME, both of which involved SNPs in the VEGFA gene. Awata et al. found that a VEGFA C-261 
634G (rs2010963) polymorphism was associated with DME (n=63) in a cohort of Japanese subjects with 262 
diabetes 
23
, and Abhary et al. found an association between the G allele of rs10434 and DME in Caucasian 263 
subjects with diabetes 
24
.  264 
VEGF-C is thought to contribute to retinal angiogenesis and increased vascular permeability through 265 
downstream effects on VEGFR-2 activation. However, the interaction between VEGFR-2, and its two 266 
ligands VEGF-A and VEGF-C is complex and not well elucidated. In the human diabetic retina, VEGFR-2 267 
expression has been shown to be greater than in non-diabetic retinas 
13,25
, and is concentrated in 268 
microvascular endothelial cells in two areas: the tips of angiogenic vessels in the peripheral retina, and the 269 
macular region 
13,25,26
. Along with the VEGFR-2 receptor, there is a pathological increase in VEGF-C and 270 
VEGF-A mRNA seen in the microvascular endothelial cells of individuals with diabetes 
25
.  271 
Advanced glycation end products (AGEs), produced in conditions of sustained hyperglycemia, bind to AGE 272 
receptors (RAGE), which induce transcription of pro-inflammatory cytokines including tumor necrosis factor 273 
(TNF). Upregulation of RAGE has also been directly implicated in the increase in VEGF-A but not VEGF-C 274 
secretion 
27
. The mechanism by which VEGF-C is increased also depends on increased levels of TNF 
25
.  275 
Zhao et al. showed that TNF found in the vitreous of patients with PDR is adequate to stimulate VEGF-C 276 
and VEGFR-2 expression in microvascular endothelial cells, but does not alter expression of VEGFR-3 
25
. In 277 
response to VEGF-A and VEGF-C binding VEGFR-2 on endothelial cells, nitric oxide production is 278 
increased, and this results in increased blood vessel permeability, and proliferation of endothelial cells 
13,26
. 279 
Furthermore, VEGF-C through binding VEGFR-2 but not VEGFR-3 has been shown to prevent TNF and 280 
hyperglycemia induced apoptosis of microvascular endothelial cells, and thus potentiate the angiogenic 281 
action of VEGF-A 
25
.  282 
It is well known that a proportion of patients with DME treated with anti-VEGF-A agents are resistant to 283 
treatment 
14
. It can be hypothesized that upregulation of other VEGFR-2 ligands such as VEGF-C, or 284 
changes in the expression of VEGFR-2 contribute to the sustained activation of the VEGFR-2 molecular 285 
pathway in such resistant patients, despite inactivation of VEGF-A. Indeed, inhibition of VEGF-A with 286 
bevacizumab has been shown to lead to enhanced VEGF-C secretion, which thereby likely compensates for 287 
the reduced VEGF-A levels 
27
. Although anti-VEGF agents have revolutionized the management of 288 
neovascular retinal diseases, including age related macular degeneration (ARMD) and fovea-involving 289 
macular edema, there is increasing evidence that treatments targeting additional pathways may be required 290 
for better treatment effect. Multikinase inhibitors (MKI) such as sorafenib and pazopanib, are promising new 291 
agents that target a number of tyrosine kinase receptors in the VEGFR family, and have been shown to 292 
significantly reduce the expression of VEGFR-1 and VEGFR-2 in human retinal pigment epithelial (RPE) 293 
cells 
28
. Phase IIa therapeutic trials using topical pazopanib eye drops for the treatment of neovascular 294 
ARMD have shown favorable results 
29
. The efficacy of pazopanib for the treatment of DR has so far been 295 
limited to a streptozotocin rat model in which topical pazopanib was shown to reduce DR-associated blood-296 
retinal-barrier breakdown 
30
. Fenofibrate, a peroxisome proliferator–activated receptor alpha (PPARα) 297 
agonist, has multiple actions including the inhibition of endothelial VEGFR-2 expression
31
. Although 298 
traditionally used as systemic therapy for patients with DM and dyslipidemia, recent experimentation in a 299 
streptozotocin rat model supports the use of topical fenofibrate eye drops as a potential therapeutic agent in 300 
diabetic retinopathy to prevent retinal inflammation, neovascularisation and edema
32
. Genetic variation in the 301 
VEGFC gene likely alters VEGF-C function or expression, which could help to explain differing responses 302 
to VEGF-A treatment. Further investigation of the functional effect of the VEGFC risk haplotype reported 303 
here for the first time, is necessary to gain a better understanding of the role of VEGF-C in DR, and thereby 304 
assist development of better treatment strategies, which in future could be tailored according to patient 305 
genotype. The manipulation of VEGF-C, either directly or at the ligand-receptor level, presents a worthwhile 306 
research direction, and is enhanced by the results of this large study suggesting that genetic variation at this 307 
locus has a significant influence on DR development.  308 
This study is the first to evaluate SNPs across the VEGFC gene in diabetes patients with and without DR. 309 
We found that genetic variation within the VEGFC gene is significantly associated with any type of DR, as 310 
well as with DME in diabetes patients. This adds to other evidence that VEGF-C and its interaction with 311 
VEFG-A and VEGFR-2 play a major functional role in the pathogenesis of DR. 312 
 313 
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Figure 1: Linkage disequilibrium between genotyped tag SNPs in and adjacent to the VEGF-C gene. The D' 408 
value for each pair of SNPs is given, multiplied by 100. A blank cell indicates D'=1.0. VEGF-C gene 409 
schematic included above linkage disequilibrium plot. 410 
 411 
 412 
Table 1: Clinical characteristics of cases with ‘Any DR’ and ‘No DR’ subdivided by T1DM and T2DM.  413 
 T1DM   T2DM   
Clinical characteristics 
No DR 
(n=205) 
Any DR 
(n=467) 
P 
Value 
No DR 
(n=775) 
Any DR 
(n=1452) 
P 
Value 
Female, n (%) 90 (43.9) 227 (48.6) 0.298 375 (48.4) 616 (42.5) 0.009 
Age, years, mean (SD) 35.3 (15.5) 47.9 (15.4) <0.001 67.0 (12.1) 65.6 (11.0) 0.001 
Duration of DM, years, mean (SD) 13.2 (9.4) 28.3 (12.5) <0.001 12.6 (7.6) 18.0 (9.4) <0.001 
HbA1c, %, mean (SD) 8.0 (1.5) 8.6 (1.7) <0.001 7.5 (1.4) 8.2 (1.7) <0.001 
BMI, mean (SD) 26.4 (4.5) 27.7 (5.8) 0.004 31.9 (6.7) 31.7 (6.6) 0.770 
Hyperlipidemia, n (%) 52 (25.5) 254 (54.9) <0.001 546 (70.6) 937 (66.0) 0.030 
Nephropathy, n (%) 22 (11.0) 138 (30.3) <0.001 184 (24.2) 494 (35.5) <0.001 
Smoking history, n (%) 79 (40.3) 210 (49.5) 0.040 400 (58.6) 618 (52.6) 0.014 
Hypertension, n (%) 51 (25.9) 257 (56.9) <0.001 566 (78.6) 1052 (78.1) 0.831 
Abbreviations: BMI, body mass index; STDR, sight threatening diabetic retinopathy; HbA1c, hemoglobin A1c; T1DM, type 1 diabetes 414 
mellitus; T2DM, type 2 diabetes mellitus; SD standard deviation. 415 
 416 
 417 
Table 2: Genotype frequencies, shown as n (%) for ‘No DR’ and ‘Any DR’ by DM type. 418 
    T1DM  T2DM  
 SNP Genotype 
No DR 
n(%) 
Any DR 
n(%) 
No DR 
n(%) 
Any DR 
n(%) 
1 rs2046462 
CC 
CT 
TT 
21 (10.3) 
79 (38.7) 
104 (51.0) 
34 (7.4) 
186 (40.4) 
240 (52.2) 
73 (9.5) 
338 (44.1) 
356 (46.4) 
136 (9.5) 
561 (39.1) 
739 (51.5) 
2 rs17697305 
CC 
CT 
TT 
1 (0.7) 
12 (8.2) 
134 (91.2) 
1 (0.3) 
31(8.3) 
340 (91.4) 
1 (0.2) 
44 (6.9) 
592 (92.9) 
1 (0.1) 
78 (5.9) 
1242 (94.0) 
3 rs17697419 
AA 
AG 
GG 
3 (1.5) 
43 (22.1) 
149 (76.4) 
2 (0.4) 
88 (19.3) 
365 (80.2) 
11 (1.5) 
144 (19.3) 
593 (79.3) 
13 (0.9) 
205 (14.6) 
1182 (84.4) 
4 rs7664413 
TT 
TC 
CC 
6 (2.9) 
57 (27.9) 
141 (69.1) 
14 (3.0) 
131 (28.1) 
321 (68.9) 
31 (4.0) 
231 (30.0) 
508 (66.0) 
63 (4.4) 
438 (30.3) 
943 (65.3) 
5 rs6828869 
CC 
CG 
GG 
41 (20.2) 
110 (54.2) 
52 (25.6) 
82 (17.6) 
222 (47.7) 
161 (34.6) 
157 (20.4) 
381 (49.5) 
232 (30.1) 
293 (20.4) 
662 (46.1) 
481 (33.5) 
6 rs17697515 
TT 
TC 
CC 
2 (1.0) 
38 (18.7) 
163 (80.3) 
1 (0.2) 
64 (13.9) 
397 (85.9) 
3 (0.4) 
123 (16.0) 
643 (83.6) 
5 (0.3) 
171 (11.9) 
1260 (87.7) 
7 rs1485766 
CC 
CA 
AA 
42 (20.7) 
104 (51.2) 
57 (28.1) 
113 (24.6) 
213 (46.3) 
134 (29.1) 
171 (22.3) 
393 (51.3) 
202 (26.4) 
370 (26.0) 
701 (49.2) 
353 (24.8) 
8 rs11947611 
AA 
AG 
GG 
38 (25.3) 
71 (47.3) 
41 (27.3) 
101 (27.1) 
170 (45.6) 
102 (27.3) 
156 (24.1) 
320 (49.5) 
170 (26.3) 
295 (22.1) 
673 (50.5) 
365 (27.4) 
9 rs9654285 
TT 
TA 
AA 
2 (1.0) 
44 (21.9) 
155 (77.1) 
7 (1.5) 
94 (20.3) 
363 (78.2) 
10 (1.3) 
174 (22.8) 
578 (75.9) 
13 (0.9) 
277 (19.3) 
1146 (79.8) 
10 rs3775195 
AA 
AC 
CC 
16 (8.0) 
86 (43.0) 
98 (49.0) 
36 (7.8) 
172 (37.1) 
255 (55.1) 
62 (8.1) 
293 (38.3) 
410 (53.6) 
115 (8.0) 
538 (37.4) 
784 (54.6) 
11 rs3775194 
GG 
GC 
CC 
36 (17.7) 
97 (47.8) 
70 (34.5) 
73 (15.7) 
216 (46.5) 
176 (37.8) 
129 (16.8) 
368 (47.9) 
272 (35.4) 
228 (15.8) 
648 (45.0) 
564 (39.2) 
12 rs2333526 
TT 
TC 
CC 
1 (0.5) 
34 (16.9) 
166 (82.6) 
1 (0.2) 
77 (16.6) 
386 (83.2) 
10 (1.3) 
141 (18.5) 
611 (80.2) 
9 (0.6) 
206 (14.3) 
1222 (85.0) 
Abbreviations: T2DM, type 2 diabetes mellitus; STDR, sight threatening diabetic retinopathy; PDR, proliferative diabetic 419 
retinopathy; DME, diabetic macular edema. STDR defined as severe NPDR or PDR, and/or DME. Controls defined as no DR or 420 
minimal NPDR. 421 
 422 
 423 
 424 
 425 
 426 
 427 
 428 
  429 
Table 3: Allelic association of VEGF-C Tag SNPs with ‘Any DR’ for all cases combined, as well as T1DM and T2DM groups individually. Results for both 430 
unadjusted and adjusted analyses are presented.  431 
Abbreviations: DM, diabetes mellitus; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; OR (95%CI), odds ratio with 95% confidence interval. *Adjusted for age, sex, duration DM, 432 
HbA1c, hypertension, nephropathy, smoking. SNPs with P < 0.05 are shown in bold. † SNPs that remained statistically significant after correction for multiple SNPs using SNP SpD method (P < 0.006).  433 
 All DM  T1DM  T2DM  
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
  
n ‘Any DR’ = 1919 
n ‘No DR’ = 980 
n ‘Any DR’ = 1197 
n ‘No DR’ = 798 
n ‘Any DR’ = 467 
n ‘No DR’ = 205 
n ‘Any DR’ = 345 
n ‘No DR’ = 187 
n ‘Any DR’ = 1452 
n ‘No DR’ = 775 
n ‘Any DR’ = 852 
n ‘No DR’ = 611 
SNP 
Minor 
allele 
OR  
(95% CI) 
P value 
OR  
(95% CI) 
P value* 
OR  
(95% CI) 
P value 
OR  
(95% CI) 
P value* 
OR  
(95% CI) 
P value 
OR  
(95% CI) 
P value* 
rs2046462 C 
0.88 
(0.79-0.99) 
0.040 
0.86 
(0.74-1.01) 
0.067 
0.91 
(0.70-1.17) 
0.444 
0.92 
(0.63-1.32) 
0.641 
0.89 
(0.77-1.01) 
0.078 
0.87 
(0.73-1.03) 
0.103 
rs17697305 C 
0.87 
(0.63-1.19) 
0.381 
1.09 
(0.73-1.65) 
0.666 
0.93 
(0.49-1.76) 
0.820 
0.79 
(0.31-2.04) 
0.630 
0.83 
(0.58-1.21) 
0.333 
1.10 
(0.69-1.76) 
0.684 
rs17697419 A 
0.75 
(0.63-0.90) 
0.002† 
0.67 
(0.52-0.85) 
0.001† 
0.78 
(0.54-1.13) 
0.192 
0.75 
(0.44-1.27) 
0.285 
0.72 
(0.58-0.89) 
0.002† 
0.65 
(0.49-0.86) 
0.003† 
rs7664413 T 
1.00 
(0.87-1.15) 
0.958 
1.01 
(0.84-1.22) 
0.891 
1.01 
(0.74-1.38) 
0.947 
0.95 
(0.60-1.50) 
0.819 
1.03 
(0.88-1.21) 
0.687 
1.03 
(0.84-1.26) 
0.766 
rs6828869 C 
0.90 
(0.81-1.00) 
0.060 0.89 
(0.77-1.03) 
0.122 
0.79 
(0.63-1.00) 
0.050 
0.69 
(0.49-0.97) 
0.035 
0.93 
(0.82-1.06) 
0.285 
0.96 
(0.82-1.12) 
0.579 
rs17697515 T 
0.72 
 (0.59-0.88) 
0.002† 
0.62 
(0.47-0.81) 
0.001† 
0.67 
(0.44-1.00) 
0.049 
0.66 
(0.36-1.18) 
0.160 
0.74 
(0.58-0.93) 
0.010 
0.62 
(0.45-0.85) 
0.003† 
rs1485766 C 
1.10 
 (0.99-1.23) 
0.075 
1.20 
(1.04-1.39) 
0.013 
1.06 
(0.84-1.34) 
0.635 
1.10 
(0.79-1.53) 
0.561 
1.11 
(0.98-1.26) 
0.098 
1.19 
(1.01-1.40) 
0.038 
rs11947611 A 
0.96 
(0.85-1.08) 
0.470 
0.92 
(0.79-1.08) 
0.290 
1.04 
(0.79-1.35) 
0.800 
1.01 
(0.68-1.48) 
0.973 
0.94 
(0.82-1.07) 
0.363 
0.93 
(0.77-1.10) 
0.382 
rs9654285 T 
0.84 
 (0.71-1.00) 
0.045 0.80 
(0.63-1.00) 
0.052 
0.97 
(0.68-1.40) 
0.875 
0.87 
(0.53-1.47) 
0.641 
0.81 
(0.67-0.98) 
0.030 
0.77 
(0.60-1.01) 
0.055 
rs3775195 A 
0.95 
(0.84-1.07) 
0.377 
0.97 
(0.83-1.14) 
0.694 
0.86 
(0.66-1.11) 
0.237 
0.80 
(0.55-1.16) 
0.233 
0.97 
(0.85-1.12) 
0.704 
1.00 
(0.83-1.19) 
0.970 
rs3775194 G 
0.91 
(0.81-1.01) 
0.077 
0.93 
(0.81-1.08) 
0.341 
0.89 
(0.71-1.13) 
0.354 
0.93 
(0.67-1.30) 
0.683 
0.91 
(0.80-1.03) 
0.124 
0.92 
(0.78-1.08) 
0.323 
rs2333526 T 
0.75 
(0.63-0.91) 
0.003† 
0.69 
(0.54-0.90) 
0.005† 
0.95 
(0.63-1.43) 
0.792 
0.98 
(0.53-1.80) 
0.938 
0.72 
(0.58-0.89) 
0.002† 
0.65 
(0.49-0.86) 
0.003† 
Table 4: Haplotype associations adjusted for clinical covariates (including DM type, age, sex, duration DM, 434 
hypertension, nephropathy, HbA1c and smoking) with any type of DR for T1DM and T2DM participants 435 
combined. 436 
 437 
Haplotype Alleles 
Haplotype 
frequency 
No DR 
frequency 
Any DR 
frequency 
OR (95%CI) P-value 
Block 1 1 2 3 4 5 6 
 
   
 
1 C T A C C T 0.065 0.085 0.061 0.59 (0.44-0.79) 0.0003† 
2 C T G T C C 0.181 0.183 0.182 0.98 (0.81-1.18) 0.835 
3 C T A C C C 0.025 0.028 0.024 0.86 (0.54-1.35) 0.513 
4 T C G C C C 0.035 0.040 0.042 0.99 (0.66-1.48) 0.969 
5 C T G C C C 0.011 0.009 0.008 1.37 (0.61-3.08) 0.446 
6 T T G C C C 0.116 0.114 0.118 1.04 (0.83-1.32) 0.722 
7 T T G C G C 0.544 0.543 0.566 1.10 (0.95-1.27) 0.188 
Block 2 7 8 9 10 11 12 
 
    
1 C A T C G T 0.074 0.092 0.072 0.65 (0.49-0.86) 0.002† 
2 A G A A G C 0.207 0.221 0.229 1.01 (0.85-1.21) 0.876 
3 C G A A G C 0.049 0.059 0.048 0.80 (0.56-1.14) 0.209 
4 A A T C G C 0.021 0.021 0.023 1.15 (0.66-2.01) 0.609 
5 A G A C G C 0.010 0.007 0.010 2.36 (0.94-5.95) 0.056 
6 A A A C C C 0.052 0.052 0.054 0.95 (0.65-1.39) 0.795 
7 C A A C C C 0.303 0.326 0.316 0.94 (0.80-1.10) 0.421 
8 A G A C C C 0.187 0.177 0.197 1.24 (1.02-1.51) 0.031 
9 C G A C C C 0.049 0.046 0.052 1.12 (0.74-1.69) 0.604 
Abbreviations: DR, diabetic retinopathy; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; HbA1c, hemoglobin A1c ; 438 
OR (95%CI), odds ratio with 95% confidence interval.  439 
Haplotypes with P < 0.05 are shown in bold.  440 
† Haplotypes that remained statistically significant after Bonferroni correction for multiple haplotype testing (Block 1: P < 0.007; 441 
Block 2: P < 0.006). 442 
 443 
 444 
Table 5: Allelic association of the top 3 VEGF-C Tag SNPs with PDR and DME, for all diabetics combined, 445 
as well as T1DM and T2DM groups individually. Results from multivariate analysis are presented here. 446 
 447 
 All DM   T1DM   T2DM   
SNP n OR (95% CI) P value n OR (95% CI) P value n OR (95% CI P value 
rs17697419: A      
PDR 433 0.80 (0.57-1.13) 0.206 184 1.24 (0.70-2.19) 0.462 249 0.66 (0.43-1.03) 0.065 
DME 425 0.81 (0.60-1.11) 0.184 64 1.07 (0.50-2.29) 0.857 361 
0.76 (0.53-1.07) 
0.112 
rs17697515: T      
PDR 433 0.76 (0.45-0.97) 0.007 184 1.04 (0.54-2.00) 0.899 249 0.52 (0.31-0.88) 0.015 
DME 425 0.61 (0.42-0.89) 0.009 64 1.18 (0.51-2.69) 0.701 361 0.53 (0.35-0.82) 0.004† 
rs2333526: T      
PDR 433 0.88 (0.62-1.24) 0.473 184 1.38 (0.71-2.68) 0.342 249 0.79 (0.52-1.20) 0.273 
DME 425 0.75 (0.55-1.03) 0.079 64 1.21 (0.54-2.75) 0.642 361 0.70 (0.49-1.00) 0.052 
Abbreviations: PDR, proliferative diabetic retinopathy; DME, diabetic macular edema; DM, diabetes mellitus; T1DM, type 1 448 
diabetes mellitus; T2DM, type 2 diabetes mellitus; OR (95%CI), odds ratio with 95% confidence interval. n represents number of 449 
cases in each subgroup. Controls totaled 952 patients (241 T1DM, 711 T2DM) with DR grading no worse than minimal NPDR. 450 
Adjusted for age, sex, duration DM, HbA1c, hypertension, nephropathy, smoking. 451 
 SNPs with P < 0.05 are shown in bold. † SNPs that remained statistically significant after correction for multiple SNPs using SNP 452 
SpD method (P < 0.006).  453 
 454 
